Twitter Beğeni Hilesi

Honored to have attended such a great meeting with amazing speakers! Thanks to Giuseppe Lo Russo and to all the faculty for organizing this outstanding event #lungcancer #letsbreaktheIce

How can we improve #clinicaltrial design in rare cancers? Great talk today by Giacomo G Baldi in Rome, and ad interesting workshop with young oncologists. New ideas are on track! Thanks #aiomgiovani! AIOM

👏🏻

What an impactful Presidential symposium at #ESMO23. THREE NEJM articles already: selpercatinib in #RET NSCLC, selpercatinib in medullary thyroid, and amivantamab with chemo in #EGFR exon 20. Congrats to Prof. Caicun Zhou - two first-author NEJM papers in one day!

Unique opportunity to present the TOMAS2 trial with trabectedin + olaparib vs trabectedin in adv STS at #ESMO23! No diff in all comers but nice data in HRd and uLMS. More to come from ongoing translational analyses. A great collaboration from Italian Sarcoma Group Sarcoma UniTo

Great to be here once again in Rome for #AIOM Congress. Many celebrations today for 50th anniversary and a wonderful presentation from my colleague and friend Achille Bottiglieri AIOM

Eletto ieri il nuovo Direttivo Nazionale AIOM. A guidare la società scientifica per i prossimi due anni saranno: Francesco Perrone , Presidente Nazionale; Massimo Di Maio, Presidente Eletto; Nicola Silvestris, Segretario Nazionale; rossanaberardi, Tesoriere. #AIOM23

A beautiful pic of #INT at #AIOM23 and good luck to Mario Occhipinti for starting his new course in #aiomgiovani working group. Bravo! 🎉

Beyond first line in #NSCLC WT: a real pleasure to listen to Giuseppe Lo Russo talking about future perspectives in this tough and challenging topic at #AIOM23 AIOM

Our work is out on ⁦JAMA Network Open⁩ ❗️ Is NALIRIFOX better than FOLFIRINOX as 1st line for metastatic #pancsm ❓ ❎similar OS and PFS, ⚠️different clinical and 💰 toxicity “I suppose we all thought that one way or another” jamanetwork.com/journals/jaman…

Thanks to Frontiers - Oncology for publishing today our report of a very rare disease successfully managed with a well known drug. Istituto Tumori Roberta Sanfilippo Sandro Pasquali Paolo G Casali

A great kick-off today in Lugano for #ESMOSarcomaAndRareCancers24! Super-honoured for having my clinical case selected for discussion in the very first young oncologist session, and a big thank to Roberta Sanfilippo and Paolo G Casali for their strong support. ESMO - Eur. Oncology

#young oncologists are a key part of rare cancers family! Thanks all for coming to our clinical case discussion! Every happy face in this picture is a reward for us in #ESMOYOC Btw. Don’t miss our Vesalius talk about work-life overload at 12.15 #ESMOSarcomaAndRareCancers24

So many intriguing sessions today at #ESMOSarcomaAndRareCancers24 day 2 and many friends to share these days with #retroperitonealsarcoma #rarecancerawareness ESMO - Eur. Oncology

Seconda edizione dell’ASCO-AIOM International Clinical Research Course: come sempre grande partecipazione ed entusiasmo. #ASCO #AIOM ASCO

An inspiring talk today by #iantannock at ASCO-AIOM clinical research course: so many critical points raised and new perspectives shared. Grateful to attend this course! AIOM

Smashing out day 1 of #aiomgiovani annual meeting: so many brilliant presentations in a wonderful location! And of course, sharing it with good old friends AIOM Fondazione Aiom

War do not stop oncology: a great message and a touching talk today in a special session at #aiomgiovani day 2 👏🏻👏🏻AIOM Fondazione Aiom

A giant among us has departed. Prof. Chris D.M.Fletcher passed away peacefully yesterday in Boston. He impacted our entire field, and he will be missed greatly. It was an honor to work with him and to learn from him.

First engineerd cell therapy approved by FDA for patients with a solid tumor: afamitresgene autoleucel accelerated approval for synovial sarcoma with MAGE-A4 antigen expression and matching HLA status! Amazing story, congratulations to everyone involved in the Adaptimmune trials!